Draft:Suzette Delaloge
 | Draft article not currently submitted for review.
This is a draft Articles for creation (AfC) submission. It is not currently pending review. While there are no deadlines, abandoned drafts may be deleted after six months. To edit the draft click on the "Edit" tab at the top of the window. To be accepted, a draft should:
It is strongly discouraged to write about yourself, your business or employer. If you do so, you must declare it. Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Last edited by DaffodilOcean (talk | contribs) 2 months ago. (Update) |
Suzette Delaloge (born 6 July 1967 Auxerre) is a French oncologist. She was awarded the Knight of the Legion of Honour in 2018.[1]
Life
[edit]In 2004, Suzette Delaloge set up the first rapid screening system for breast cancer. In 2016, in an article in the newspaper Le Monde, she returned to screening where she explained that this "public health issue has become a political issue".[2]
She is the coordinator of the MyPebs programme, an international project funded by the European Union to evaluate the benefits of personalised breast cancer screening in 85,000 women aged 40 to 70. This is the first study to recruit so many patients .[3]
Medical career
[edit]From 2004 to 2021, Suzette Delaloge was Head of the Breast Pathology Department at the Institut Gustave-Roussy (IGR),. In 2022, she is the director of the personalized cancer prevention program .
In 2015, she co-signed, with other personalities of the French medical world such as David Khayat, a letter for the right to be forgotten of cured patients published in the newspaper Libération.
In 2016, she changed her treatment from docetaxel to paclitaxel for breast cancer, in the interest of her patients. According to her, a metabolite or impurity could be the cause of a series of deaths, the first of which was a patient of the IGR.[4]
She is a regular contributor to Le Monde and Le Figaro to provide an expert point of view. She talks about the risks of hair straightening products that increase the risk of uterine cancer,[5] or getting a second medical opinion after diagnosis.[6]
Medical research
[edit]Suzette Delaloge has published more than 220 peer-reviewed publications and presented more than 700 times at international conferences,.[7]
She is an editor on breast cancer for the European Journal of Cancer and is on the steering committee of the European Society of Medical Oncology.
External links
[edit]- Suzette Delaloge publications indexed by Google Scholar
References
[edit]- ^ "Légion d'honneur : des femmes médecins et chercheuses à l'honneur". Le Quotidien du Médecin (in French). Retrieved 2024-03-12.
- ^ "Dépistage du cancer du sein : « il faut prévenir les risques d'inégalité d'accès à la prévention et au dépistage »". Le Monde.fr (in French). 2016-10-10. Retrieved 2024-03-12.
- ^ "Cancer du sein : le pari d'un dépistage personnalisé". Les Echos (in French). 2018-09-30. Retrieved 2024-03-12.
- ^ "Docétaxel : "Sept décès dans l'année, ce n'est pas un hasard"". Le Point (in French). 2017-02-23. Retrieved 2024-03-12.
- ^ "Cancer du sein : le pari d'un dépistage personnalisé". Les Echos (in French). 2018-09-30. Retrieved 2024-03-12.
- ^ "Un site internet propose d'obtenir un deuxième avis médical". Le Figaro (in French). 2017-10-20. Retrieved 2024-03-12.
- ^ "Suzette Delaloge | ESMO". www.esmo.org. Retrieved 2024-03-12.